New drug AV-001 aims to help hospitalized pneumonia patients breathe easier
NCT ID NCT05123755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called AV-001 in 120 hospitalized adults with pneumonia who need extra oxygen. The drug is given daily for up to 28 days alongside standard care. The goal is to see if it is safe and helps patients recover faster from pneumonia caused by COVID-19 or other respiratory infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Denver Health Medical Center
RECRUITINGDenver, Colorado, 80203, United States
-
Henry Ford Health System
RECRUITINGDetroit, Michigan, 48202, United States
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92658-6100, United States
-
MedStar Health Research Institute, Inc.
RECRUITINGHyattsville, Maryland, 20782, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Can a Lung-Opening maneuver change a key injury marker in ARDS?
- Could simply sitting up ease breathing in severe lung failure?